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Objective. Existing criteria for the classification
of gout have suboptimal sensitivity and/or specificity,
and were developed at a time when advanced imaging
was not available. The current effort was undertaken to
develop new classification criteria for gout.
Methods. An international group of investigators,
supported by the American College of Rheumatology
and the European League Against Rheumatism, con-
ducted a systematic review of the literature on advanced
imaging of gout, a diagnostic study in which the presence
of monosodium urate monohydrate (MSU) crystals in
synovial fluid or tophus was the gold standard, a ranking
exercise of paper patient cases, and a multicriterion deci-
sion analysis exercise. These data formed the basis for
developing the classification criteria, which were tested
in an independent data set.
Results. The entry criterion for the new classifica-
tion criteria requires the occurrence of at least 1 episode
of peripheral joint or bursal swelling, pain, or tenderness.
The presence of MSU crystals in a symptomatic joint/
bursa (i.e., synovial fluid) or in a tophus is a sufficient cri-
terion for classification of the subject as having gout, and
does not require further scoring. The domains of the new
classification criteria include clinical (pattern of joint/
bursa involvement, characteristics and time course of
symptomatic episodes), laboratory (serum urate, MSU-
negative synovial fluid aspirate), and imaging (double-
contour sign on ultrasound or urate on dual-energy com-
puted tomography, radiographic gout-related erosion).
The sensitivity and specificity of the criteria are high
(92% and 89%, respectively).
Conclusion. The new classification criteria, devel-
oped using a data-driven and decision analytic approach,
have excellent performance characteristics and incorpo-
rate current state-of-the-art evidence regarding gout.
Introduction
Gout, which is characterized by deposition of
monosodium urate monohydrate (MSU) in synovial flu-
id and other tissues, is the most common form of inflam-
matory arthritis, with a prevalence of 3.9% in the US
(1), 0.9% in France (2,3), 1.4 – 2.5% in the UK (4–6),
1.4% in Germany (5), and 3.2% (European ances-
try)26.1% (Maori ancestry) in New Zealand (7). Over
the last decade, several new therapies for gout have
been approved by regulatory agencies or are being test-
ed (8). The conduct of trials that lead to drug approval,
and of observational studies that provide insights into
risk factors, genetic associations, and general epidemiol-
ogy of gout, is critically dependent on appropriate iden-
tification of individuals with gout for inclusion in such
studies. Classification criteria serve the purpose of
enabling standardized assembly of a relatively homoge-
neous group of individuals with the disease of interest
for enrollment into such studies (9).
There are several existing sets of classification
criteria or diagnostic rules for gout (10–14), with the
most widely used being the 1977 American Rheumatism
Association (now the American College of Rheumatolo-
gy [ACR]) preliminary criteria for the classification of
the acute arthritis of primary gout (10). These prelimi-
nary criteria were intended for identifying the acute
arthritis of gout and not necessarily for intercritical
gout, the spectrum of comparator diseases was limited,
and physician diagnosis was the gold standard. In a
recent study in which the gold standard was MSU crystal
status in synovial fluid or nodule aspirate among indi-
viduals with a broad range of diagnoses, the sensitivity
of existing criteria sets (10–14) ranged from 57.6% to
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100% (i.e., 100% with MSU crystal identification as suf-
ficient for classification as gout), whereas the specificity
ranged from 34.3% to 86.4%, with no single criteria set
having both excellent sensitivity and excellent specificity
(15,16). Such findings highlight the need for classifica-
tion criteria with improved performance characteristics,
with higher specificity likely to be favored in order to
ensure that individuals enrolled into trials for treat-
ments with unclear efficacy and safety truly have gout.
Accurate classification of gout without crystal
documentation for recruitment into studies is also need-
ed, since the majority of cases of gout are managed in
primary or acute care settings (17,18), where synovial
fluid aspiration and polarizing microscopy are not com-
monly performed. Additionally, the existing published
criteria were developed at a time when advanced imag-
ing modalities, such as ultrasonography or dual-energy
computed tomography (DECT), had not been studied;
their utility for gout classification in the context of other
clinical and laboratory parameters is not known.
To address these issues, an international collabo-
rative working group to develop new classification criteria
for gout was convened with the support of the ACR and
the European League Against Rheumatism (EULAR)
(19). The final results are reported here.
Methods
The major steps taken to develop the new classifica-
tion criteria are outlined in Figure 1.
Phase 1. To identify factors to be considered for the
content of classification criteria for gout, 3 studies were
undertaken (Figure 1). First, clinicians with expertise in gout
and patients with gout identified factors they believed to dis-
criminate gout from other rheumatic diseases in a Delphi
exercise (20). Second, we tested items from this Delphi exer-
cise that were agreed to be potentially discriminatory for
gout and items from existing classification criteria in a cross-
sectional diagnostic study (Study for Updated Gout Classifi-
cation Criteria [SUGAR]) (21). Briefly, this study included
983 consecutive subjects (exceeding the recruitment target of
860) who had had joint swelling or a subcutaneous nodule
within the previous 2 weeks, either of which was judged to be
conceivably due to gout. These subjects were recruited from
rheumatology clinics in 16 countries. All subjects were
required to undergo aspiration of the symptomatic joint or
nodule, with crystal examination performed by a certified
observer (21,22), and imaging (ultrasound, radiography).
Those who were MSU crystal positive were designated as
cases while those who were MSU crystal negative were desig-
nated as controls, irrespective of clinical diagnosis. Analyses
in the SUGAR study were conducted among two-thirds of
the sample (derivation data set; n5 653); the other one-third
(n5 330) were analyzed as the validation data set for the
final criteria. Third, we conducted a systematic literature
review of advanced imaging modalities for classifying gout
(23).
Phase 2. Rationale. It was recognized that the SUGAR
study and the imaging review may have some limitations. The
SUGAR study might have been prone to selection bias as
MSU crystal positivity was required in order for a subject to be
considered a case; this may have introduced bias toward larger
joints, more severe disease, and/or tophaceous disease. In
addition, subjects were recruited from rheumatology clinics,
which may have contributed to spectrum bias since most
patients with gout are seen in primary care settings. The sys-
tematic literature review of imaging was limited by the relative
paucity of published data, and comparator diseases included
were limited. Thus, Phase 2 was envisioned as a complementa-
Figure 1. Flow chart of the study process. The major steps taken to develop the new American College of Rheumatology/European League
Against Rheumatism criteria for classification of gout are outlined. SUGAR5 Study for Updated Gout Classification Criteria.
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ry phase that would incorporate the data derived in Phase 1
with clinical expertise to address a broader spectrum of clinical
gout.
Approach to identifying domains and categories. In
Phase 2, an international panel of expert rheumatologists and
primary care physicians used a multicriterion decision analytic
consensus methodology, informed by data generated in Phase
1, to determine the factors that best discriminated gout from
other rheumatic diseases that could conceivably be considered
in the differential diagnosis. Such an approach would lead to
expert-derived, data-informed weighting of discriminating fac-
tors. The specific methods are described below.
Rheumatologists and general internists with an inter-
est in gout submitted paper patient cases of patients for whom
gout was in the differential diagnosis, using standardized data
collection forms. A subset of 30 paper patient cases was select-
ed to represent a broad spectrum of the probability of gout.
Prior to the in-person expert panel meeting, panel members
were given the data from Phase 1 to review, and they were
asked to rank-order the 30 paper patient cases from lowest to
highest probability of having gout.
At the in-person expert panel meeting, held over 2 days
(June 9–10, 2014 in Paris, France in advance of the EULAR
Congress), 3 concepts were agreed upon a priori. First, the task
was to develop criteria that would enable standardized assem-
bly of a well-defined, relatively homogeneous group of subjects
representative of persons with gout, for entry into observational
studies or clinical trials. Such criteria are not intended to cap-
ture all possible patients, but rather to capture the great majori-
ty of patients with shared key features of gout. Second, the
classification was to apply to the patient’s total disease experi-
ence, not to classify individual symptomatic episodes. Third,
elements of the criteria could be accrued over time such that
individuals could fulfill criteria at a later time point even if they
did not at the initial assessment.
Review of the Phase 1 data and the paper patient case
ranking exercise formed the basis for in-depth discussion to
identify key features that were pertinent to the probability of
gout. Based on these key features, initial formulation of poten-
tial criteria was developed, with consideration of entry, suffi-
cient, and exclusion criteria, and more precise definition of
domains and their categories. Decisions regarding domains
and their categories were supported, where possible, by Phase
1 data and/or any other available published evidence.
Approach to assigning relative weights to domains and
categories. Once the Paris panel agreed upon preliminary do-
mains and categories, the members undertook a discrete-choice
conjoint analysis exercise guided by an experienced facilitator
(RPN) and aided by a rheumatologist with experience in the
process (TN), similar to that used for other classification crite-
ria (e.g., rheumatoid arthritis, systemic sclerosis) (24–29). Spe-
cifically, we used a computer software program, 1000Minds
(www.1000minds.com), which utilizes decision science theory
and computer adaptive technology to carry out a series of dis-
crete forced-choice experiments through pairwise ranking of
alternatives that lead to quantified weights of each domain and
each category within the domains (28,30). Briefly, the expert
panel was presented with a series of paired scenarios, each of
which contained the same 2 domains, but with different combi-
nation of the domains’ categories grouped together in each sce-
nario. The panel was instructed to assume that all other
parameters were equivalent between the 2 patients represented
by the scenarios. The distribution of votes (percent who voted
for “A,” “B,” or “equal probability”) was presented for each
pair of scenarios after each vote. Discussion occurred after
each vote, with re-voting as necessary. Consensus was consid-
ered to have been achieved when all participants either indicat-
ed complete agreement as to which scenario represented a
higher probability of gout, or indicated that they could accept
the majority opinion.
Relative weights were derived with the decision analytic
software, based on the voting results of the discrete-choice sce-
narios and refined by each successive result. Upon completion
of the voting exercise, the relative weights for each category and
domain, and the face validity of the resulting rank order of 10
paper patient cases, were reviewed.
After the in-person meeting, minor scoring simplifica-
tions were incorporated and pretested in the SUGAR deriva-
tion data set (i.e., the original two-thirds sample analyzed in
Phase 1). A cutoff score that maximized the sum of sensitivity
and specificity was determined, to examine misclassification.
Approach to developing final criteria scoring. The raw
weights from the scoring system were simplified into whole
numbers, with performance characteristics assessed for each
simplification.
Approach to defining criteria threshold for classifying
gout. The original 30 paper patient cases (except for 3 with
demonstrated MSU crystals), in addition to 20 subjects from
the SUGAR study analyzed in Phase 1 who had unique scores
close to the cutoff score derived as described above, were used
for a threshold identification exercise. For these 20 subjects, if
synovial fluid microscopy had failed to show MSU crystals, this
information was provided. Otherwise, the results of synovial
fluid examination were recorded as “not done.” This informa-
tion was not made known to the expert panel. These cases
were arranged according to their score in descending order. In
an online exercise, the expert panel indicated whether they
would classify the patient as having gout with sufficient confi-
dence to feel comfortable enrolling that patient into a Phase 3
trial of a new urate-lowering agent.
Testing of the new gout classification criteria and com-
parison with existing published criteria. The final criteria set
was evaluated in the SUGAR validation data set (i.e., the one-
third of the data set that had not been used for any analyses to
date [n5 330]); the purpose of this was to enable validation of
the newly developed criteria in an independent data set. A sec-
ondary analysis was conducted to evaluate how the criteria
would perform if only clinical parameters were available (i.e.,
without MSU determination or imaging). The performance
characteristics of the new criteria were compared with those of
existing published criteria using logistic regression.
Results
The expert panel (n5 20) comprised 19 physicians
with a clinical and/or research interest in gout (17 clinical
rheumatologists and 2 primary care physicians) and an epi-
demiologist/biostatistician; 9 members of the panel were
from the US, 8 from Europe, 2 from New Zealand, and 1
from Mexico. One hundred thirty-three paper cases were
submitted by the expert panel and 79 clinical rheumatolo-
gists and general internists.
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Based on review of the Phase 1 data and the rank-
ing exercise with the 30 cases representing low to high
probability of gout, initial key factors that were identified
as being important for classifying gout were presence of
MSU crystals, pattern of joint involvement, intensity of
symptomatic episodes, time to maximal pain and to reso-
lution, episodic nature of symptoms, presence of clinical
tophus, level of serum urate, imaging features, response
to treatment, family history, and risk factors or associat-
ed comorbidities. The last 3 factors were not considered
further as they are not features of gout itself despite their
association with gout, and inclusion of risk factors or
Table 1. Definitions and considerations for each domain*
Domain† Definitions and special considerations
1. Pattern of joint/bursa involvement
during symptomatic episode(s) ever
Categories are defined as per the
description of the distribution of joints involved
Distribution of joints: involvement (ever) of
i) Joint(s) or bursa(e) other than ankle, midfoot or first metatarsophalangeal
(MTP) joint (or their involvement only as part of a polyarticular presentation)
ii) Ankle or midfoot joint(s) as monoarticular or part of an oligoarticular pre-
sentation without first MTP joint involvement
iii) MTP joint involvement as monoarticular or part of an oligoarticular
presentation
2. Characteristics of symptomatic episode(s) ever
Categories are defined as
No characteristics present
1 characteristic present
2 characteristics present
3 characteristics present
Characteristics to consider: presence (ever) of
i) Great difficulty with walking or inability to use the affected joint(s) during a
symptomatic episode ever (patient-reported)
ii) Can’t bear touch or pressure to the affected joint during a symptomatic epi-
sode ever (patient-reported)
iii) Erythema overlying affected joint during a symptomatic episode ever
(patient-reported or physician-observed)
3. Time course of symptomatic episode(s) ever
Categories are defined as
No typical episodes
1 typical episode
Recurrent typical episodes
“Typical symptomatic episode”: presence (ever) of .2 of the following, irrespective of
antiinflammatory treatment
i) Time to maximal pain ,24 hours
ii) Resolution of symptoms in #14 days
iii) Complete resolution (to baseline level) between symptomatic episodes
4. Clinical evidence of tophus
Categories are defined as
Present
Absent
Appearance: draining or chalk-like subcutaneous nodule under transparent skin, often
with overlying vascularity (Figure 2)
Location: classic locations—joints, ears, olecranon bursae, finger pads, tendons
(e.g., Achilles)
5. Serum urate level, off-treatment
Categories are defined as
,4 mg/dl (0.24 mmoles/liter)
4–,6 mg/dl (0.24–,0.36 mmoles/liter)
6–,8 mg/dl (0.36–,0.48 mmoles/liter)
8–,10 mg/dl (0.48–,0.60 mmoles/liter)
$10 mg/dl ($0.60 mmoles/liter)
Which serum urate measurement to use: highest reading on record, off urate-lowering
therapy
Special considerations: Ideally, the serum urate level should be scored if tested at a
time when the patient was not receiving urate-lowering therapy and it was .4
weeks from the start of an episode; if practicable, retest under those conditions.
If serum urate level is $10 mg/dl, no need to retest.
6. Synovial fluid analysis
Categories are defined as
MSU negative
Not done
Location: symptomatic (ever) joint or bursa
Special considerations: Assessment should be performed by a trained observer.
Note: MSU positive is a sufficient criterion.
7. Imaging evidence of urate deposition
Categories are defined as
Absent or not done
Present (either modality)
Modality: ultrasound or DECT
Appearance: double-contour sign on ultrasound (Figure 3A)‡ or urate deposition on
DECT (Figure 3B)§
Location: symptomatic (ever) joint or bursa
8. Imaging evidence of gout-related
joint damage
Categories are defined as
Absent or not done
Present
Modality: radiography
Appearance of gout-related erosion: cortical break with sclerotic margin and
overhanging edge; excludes gull wing appearance (Figure 3C)
Location: radiograph of hands and/or feet; excludes distal interphalangeal joints
* Symptomatic (ever) refers to pain and/or swelling.
† Categories within each domain are hierarchical; if a subject fulfills more than 1 category, the highest category should be selected.
‡ A false-positive double-contour sign (artifact) may appear at the cartilage surface, but should disappear with a change in the insonation angle
of the probe (31,32).
§ Images should be acquired using a dual-energy computed tomography (DECT) scanner, with data acquired at 80 kV and 140 kV and analyzed
using gout-specific software with a 2-material decomposition algorithm that color-codes urate (33). A positive scan result is defined as the pres-
ence of color-coded urate at articular or periarticular sites. Nailbed, submillimeter, skin, motion, beam hardening, and vascular artifacts should
not be interpreted as DECT evidence of urate deposition (34).
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comorbidities in the definition of gout would preclude
future studies evaluating their association with gout.
Entry, sufficient, and exclusion criteria. Before
embarking upon defining domains and domain catego-
ries (the classification criteria), we defined entry, suffi-
cient, and exclusion criteria. The entry criteria were
intended to be used to identify the relevant patient pop-
ulation to whom the classification criteria would be
applied. Sufficient criteria were intended to define fea-
tures such as a gold standard that alone could classify
gout without further need to apply the classification cri-
teria scoring system. Exclusion criteria were intended to
define individuals in whom gout could be ruled out
(among those who met entry criteria) and to whom the
classification criteria should not be further applied. The
expert panel agreed that these classification criteria
should be applicable only to people with symptomatic
disease because the prognosis of asymptomatic disease is
presently not well delineated in the literature, and to
enable categorization based on features of symptomatic
episodes. The entry criterion was defined as the occur-
rence of at least 1 episode of swelling, pain, or tenderness
in a peripheral joint or bursa. The sufficient criterion was
defined as the presence of MSU crystals in a symptomat-
ic joint or bursa (i.e., in synovial fluid) or tophus as
observed by a trained examiner. The panel agreed that
there would be no exclusion criteria because gout can
often coexist with other diseases and because synovial
fluid microscopy can sometimes fail to disclose MSU
crystals in patients with gout for technical, sampling, or
treatment reasons.
Domains and categories. Based on the key fea-
tures identified initially, Phase 1 data, and available pub-
lished literature, and with a defined population to whom
the criteria would apply, the expert panel further devel-
oped the pertinent domains and their respective catego-
ries in an iterative process. The expert panel aimed to
define relevant clinical and imaging parameters to be as
specific as possible for gout.
The domains included clinical parameters (num-
bers 1 – 4), laboratory parameters (numbers 5 and 6), and
imaging parameters (numbers 7 and 8). The specific
domains and their respective definitions are summarized
in Table 1. The domains were designed to be scored
based on the totality of the subjects’ symptomatic disease
experience. All of the categories within domains are hier-
archical and mutually exclusive, such that if both a higher
and a lower category have been fulfilled at different
points in time, the higher one should be scored; the high-
est categories are listed last within each domain.
Symptomatic episodes were defined as those in
which there was swelling, pain, or tenderness in a
peripheral joint or bursa. For the pattern of joint
involvement, it was agreed that first metatarsophalan-
Figure 2. Examples of tophus. The tophus is defined as a draining or chalk-like subcutaneous nodule under transparent skin, often with overly-
ing vascularity. Typical locations are the ear (A), the elbow (olecranon bursa) (B), and the finger pulps (C and D). Note the overlying vascularity
in D.
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geal joint, ankle, or midfoot involvement as part of a
polyarticular presentation, though possible in gout, was
not specific enough for gout since that pattern could be
seen commonly in other disorders such as rheumatoid
arthritis. The time course of symptomatic episodes was
to be considered irrespective of antiinflammatory treat-
ment. For clinical tophus, a precise definition in terms
of appearance and location was developed to assist in
differentiation from other subcutaneous nodules that
may be confused with tophi. Examples of clinically evi-
dent tophi are provided in Figure 2. Serum urate was
considered a mandatory element of the classification cri-
teria scoring system (i.e., the score cannot be computed
without a serum urate value). For the synovial fluid
domain, the fluid must be aspirated from a symptomatic
(ever) joint or bursa, and assessed by a trained observer.
If the synovial fluid aspirate was MSU positive, the indi-
vidual would have been classified as having gout under
the sufficient criterion without evaluating the rest of the
classification criteria.
For imaging evidence of urate deposition, the
imaging modalities with sufficient published data and
investigator experience to support their utility in identi-
fying urate deposition accurately were ultrasound and
DECT. Magnetic resonance imaging and conventional
CT did not have sufficient published data or investigator
experience to support their consideration. For ultra-
sound evidence of urate deposition, the required finding
is the double-contour sign (DCS), defined as hypere-
choic irregular enhancement over the surface of the hya-
line cartilage that is independent of the insonation angle
of the ultrasound beam (note: false-positive DCS [arti-
fact] may appear at the cartilage surface but should dis-
appear with a change in the insonation angle of the
probe) (31,32). Examples of gout-related DCS are pro-
vided in Figure 3. For DECT, urate deposition is
defined as the presence of color-coded urate at articular
or periarticular sites (Figure 3). Images should be
acquired using a DECT scanner, with data acquired at
80 kV and 140 kV and analyzed using gout-specific soft-
ware with a 2-material decomposition algorithm that
color-codes urate (33). A positive scan result is defined
as the presence of color-coded urate at articular or peri-
articular sites. Nailbed, submillimeter size, skin, motion,
beam hardening, and vascular artifacts should not be
interpreted as DECT evidence of urate deposition (34).
The scoring of this imaging domain is applicable only to
a symptomatic (ever) joint or bursa (i.e., swelling, pain,
or tenderness), and is scored as present on either
modality, or absent/not done (i.e., neither modality was
performed). That is, if either imaging modality demon-
strates the required finding, then urate deposition is
considered to be present.
Finally, imaging evidence of gout-related joint
damage is to be scored on the basis of conventional radi-
ography of the hands and/or feet demonstrating at least
1 gout-related erosion, which is defined as a cortical
break with sclerotic margin and overhanging edge (Fig-
ure 3). The distal interphalangeal joints and gull wing
appearance should be excluded from this evaluation
since they can occur in osteoarthritis.
Assigning relative weights to domains and cate-
gories. Once the domains and categories were defined,
the expert panel undertook a series of discrete-choice
experiments. This work resulted in weights being
assigned to each category and domain, such that the
highest category of each domain summed to a total of
100%. Any necessary revisions to the categories were
Figure 3. Examples of imaging features included in the classification
criteria. A, Double-contour sign seen on ultrasonography. Left panel
shows a longitudinal ultrasound image of the femoral articular carti-
lage; right panel shows a transverse ultrasound image of the femoral
articular cartilage. Both images show hyperechoic enhancement over
the surface of the hyaline cartilage (images kindly provided by Dr.
Esperanza Naredo, Hospital Universitario Gregorio Mara~non,
Madrid, Spain). B, Urate deposition seen on dual-energy computed
tomography. Left panel shows urate deposition at the first and fifth
metatarsophalangeal joints; right panel shows urate deposition within
the Achilles tendon. C, Erosion, defined as a cortical break with
sclerotic margin and overhanging edge, seen on conventional radiog-
raphy of the first metatarsophalangeal joint.
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Table 2. The ACR/EULAR gout classification criteria*
Categories Score
Step 1: Entry criterion (only apply criteria below to those meet-
ing this entry criterion)
At least 1 episode of swelling, pain, or tenderness in a
peripheral joint or bursa
Step 2: Sufficient criterion (if met, can classify as gout without
applying criteria below)
Presence of MSU crystals in a symptomatic joint or
bursa (i.e., in synovial fluid) or tophus
Step 3: Criteria (to be used if sufficient criterion not met)
Clinical
Pattern of joint/bursa involvement during
symptomatic episode(s) ever†
Ankle or midfoot (as part of monoarticular or oligoar-
ticular episode without involvement of the first
metatarsophalangeal joint
1
Involvement of the first metatarsophalangeal joint (as
part of monoarticular or oligoarticular episode)
2
Characteristics of symptomatic episode(s) ever
 Erythema overlying affected joint (patient- reported or
physician-observed)
 Can’t bear touch or pressure to affected joint
 Great difficulty with walking or inability to use affected
joint
One characteristic 1
Two characteristics 2
Three characteristics 3
Time course of episode(s) ever
Presence (ever) of $2, irrespective of
antiinflammatory treatment:
One typical episode 1
2
 Time to maximal pain ,24 hours
 Resolution of symptoms in #14 days
 Complete resolution (to baseline level) between symp-
tomatic episodes
Recurrent typical episodes
Clinical evidence of tophus (Figure 2)
Draining or chalk-like subcutaneous nodule under trans-
parent skin, often with overlying vascularity, located in
typical locations: joints, ears, olecranon bursae, finger
pads, tendons (e.g., Achilles)
Present 4
Laboratory
Serum urate: Measured by uricase method.
Ideally should be scored at a time when the patient was
not receiving urate-lowering treatment and it was .4
weeks from the start of an episode (i.e., during intercriti-
cal period); if practicable, retest under those conditions.
The highest value irrespective of timing should be scored.
,4 mg/dl (,0.24 mmoles/liter)‡
6–8 mg/dl (0.36–,0.48 mmoles/liter)
8–,10 mg/dl (0.48–,0.60 mmoles/liter)
$10 mg/dl ($0.60 mmoles/liter)
24
2
3
4
Synovial fluid analysis of a symptomatic (ever)
joint or bursa (should be assessed by a
trained observer)§
MSU negative 22
Imaging (Figure 3)¶
Imaging evidence of urate deposition in
symptomatic (ever) joint or bursa:
ultrasound evidence of double-contour sign#
or DECT demonstrating urate deposition**
Present (either modality) 4
Imaging evidence of gout-related joint damage:
conventional radiography of the hands
and/or feet demonstrates at least 1 erosion††
Present 4
* A web-based calculator can be accessed at: http://goutclassificationcalculator.auckland.ac.nz, and through the American College of Rheumatol-
ogy (ACR) and European League Against Rheumatism (EULAR) web sites.
† Symptomatic episodes are periods of symptoms that include any swelling, pain, and/or tenderness in a peripheral joint or bursa.
‡ If serum urate level is ,4 mg/dl (,0.24 mmoles/liter), subtract 4 points; if serum urate level is $42,6 mg/dl ($0.242,0.36 mmoles/liter),
score this item as 0.
§ If polarizing microscopy of synovial fluid from a symptomatic (ever) joint or bursa by a trained examiner fails to show monosodium urate
monohydrate (MSU) crystals, subtract 2 points. If synovial fluid was not assessed, score this item as 0.
¶ If imaging is not available, score these items as 0.
# Hyperechoic irregular enhancement over the surface of the hyaline cartilage that is independent of the insonation angle of the ultrasound
beam (note: false-positive double-contour sign [artifact] may appear at the cartilage surface but should disappear with a change in the insonation
angle of the probe) (31,32).
** Presence of color-coded urate at articular or periarticular sites. Images should be acquired using a dual-energy computed tomography
(DECT) scanner, with data acquired at 80 kV and 140 kV and analyzed using gout-specific software with a 2-material decomposition algorithm
that color-codes urate (33). A positive scan is defined as the presence of color-coded urate at articular or periarticular sites. Nailbed, submillime-
ter, skin, motion, beam hardening, and vascular artifacts should not be interpreted as DECT evidence of urate deposition (34).
†† Erosion is defined as a cortical break with sclerotic margin and overhanging edge, excluding distal interphalangeal joints and gull wing appearance.
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made with subsequent repetition of the discrete-choice
experiments after any such changes.
A sample of 10 paper patient cases (from among
the original 30 paper cases) was scored and rank-
ordered with this preliminary scoring system. The cases
were accurately ranked with reference to the expert pan-
el’s premeeting rankings, lending face validity to this
preliminary scoring system. The scoring was also repeat-
ed without the imaging domains, which resulted in little
change in the rank-ordering. Correlation between pre-
meeting mean ranking and the initial scoring system
ranking was high (r25 0.71).
Defining criteria threshold for classifying gout.
Using a cutoff score that maximized the sum of sensitivity
and specificity from the SUGAR data, the percentage of
false-negatives and false-positives was 13.9% and 10.5%,
respectively. Next, the expert panel performed a threshold
identification exercise designed to assess the members’
willingness to enroll 47 paper cases, based on having suffi-
cient confidence that the individual has gout, into a Phase
3 randomized clinical trial of a new urate-lowering agent
with unclear efficacy and safety. The score at which the
majority considered an individual as having gout or not
fell at the same threshold as that identified as the cutoff
score that maximized the sum of sensitivity and specificity.
Final criteria scoring. With face validity of the
initial scoring system confirmed and a threshold identi-
fied, the raw relative weights of the domain categories
and the threshold score were rescaled and rounded into
whole numbers to make the scoring system as simple as
possible, while retaining the relative weighting produced
by the expert panel. The maximum possible score in the
final criteria is 23. A threshold score of $8 classifies an
individual as having gout.
A unique aspect of the new classification criteria
is that there are 2 categories that elicit negative scores.
Specifically, if the synovial fluid is MSU negative, 2
points are subtracted from the total score. Similarly, if
the serum urate level is ,4 mg/dl (,0.24 mmoles/liter),
4 points are subtracted from the total score. This
approach was taken to emphasize that these findings
reduce the probability of gout. The lowest category in
each domain has a score of 0 and is therefore not explic-
itly depicted in the final criteria table; however, for
serum urate level, the category that receives a score of 0
is 42,6 mg/dl (0.242,0.36 mmoles/liter). If imaging is
not performed, those categories are also scored as 0.
The final criteria are presented in Table 2. A web-based
calculator can be accessed at http://goutclassificationcal-
culator.auckland.ac.nz, as well as through the ACR and
EULAR web sites.
Results of testing of the new gout classification
criteria and comparison with existing published criter-
ia. In the SUGAR validation data set (n5 330), the sen-
sitivity of the new classification criteria was 0.92, and
specificity was 0.89 (Table 3). The performance of the
criteria was also tested using only clinical parameters,
i.e., without MSU results, scored as 0 (unknown/not
done) and without imaging (i.e., radiographic, ultra-
sound, or DECT imaging) results, scored as 0; this latter
Table 3. Performance of the gout classification criteria in the Study for Updated Gout Classification
Criteria validation data set, in comparison with existing published criteria
Criteria set (ref.)
Area
under the
curve*
Sensitivity
at published
threshold
Specificity
at published
threshold
ACR/EULAR criteria 0.95 0.92 0.89
ACR/EULAR criteria (clinical-only)† 0.89 0.85 0.78
ACR 1977 criteria (full) (9) 0.83 1.00‡ 0.51‡
ACR 1977 (survey) (9) 0.83 0.84‡ 0.62‡
Rome (12) 0.95 0.97 0.78‡
Rome (clinical) (12) NA 0.77‡ 0.78‡
New York (13) 0.83 1.00‡ 0.78‡
New York (clinical) (13) NA 0.79‡ 0.78‡
Mexico (11) 0.84 1.00‡ 0.44‡
Mexico (clinical) (11) NA 0.95 0.44‡
Netherlands (10)§ 0.87 0.95 0.59‡
* Based on the sum of the number of items present, or the total score in the case of weighted criteria
(American College of Rheumatology [ACR]/European League Against Rheumatism [EULAR] criteria
and Netherlands criteria). NA5 not applicable.
† Without synovial fluid microscopy or imaging.
‡ P , 0.05 versus the ACR/EULAR criteria.
§ The Netherlands criteria set was intended as a diagnostic aid, and has 2 possible cutoffs (see Supple-
mentary Table 1, on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39254/abstract); we used the higher cutoff for these analyses because such a score is deemed to sug-
gest gout.
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scoring was in keeping with similar weighting being given
to imaging studies that were negative versus not being
performed in the discrete-choice experiments. In this
setting, the sensitivity and specificity were 0.85 and 0.78.
When compared with existing published criteria
(using their respective published thresholds), the new
classification criteria performed well. For some existing
criteria sets, presence of MSU crystals alone is sufficient
to fulfill criteria; they are therefore 100% sensitive by
definition. The new gout classification criteria also have
MSU positivity as a sufficient criterion for classification,
but the criteria set was not assessed in that regard, to
avoid circularity. When the new classification criteria set
was compared in its complete form (i.e., incorporating
imaging and MSU data) with other published “full” cri-
teria, some existing criteria had higher sensitivity, but all
had lower specificity (Table 3). Additionally, for the
clinical-parameters-only version of the new criteria, the
sensitivity was better than that of all but 1 of the other
clinical-only criteria sets, and the specificity was similar
or better. The new gout classification criteria therefore
performed well in both the “full” form and the “clinical-
only” form.
Discussion
The new ACR/EULAR gout classification crite-
ria represent an international collaborative effort that
incorporates the latest published evidence on imaging
modalities, a data-driven approach with MSU identifica-
tion as a gold standard to reference key features, and a
decision analytic approach to inform the weighting of
the scoring system. This classification criteria set will
enable a standardized approach to identifying a relative-
ly homogeneous group of individuals who have the clini-
cal entity of gout for enrollment into studies. The
criteria permit characterization of an individual as hav-
ing gout regardless of whether he or she is currently
experiencing an acute symptomatic episode and regard-
less of any comorbidities. The new classification criteria
have superior performance characteristics, with high
sensitivity and improved specificity compared with pre-
viously published criteria. Arguably, specificity (leading
to high positive predictive value) is of critical impor-
tance in most clinical studies since investigators need to
have confidence that individuals who are enrolled in a
study truly have the condition of interest.
Gout is unlike other rheumatic diseases in that a
gold standard assessment is available, i.e., MSU crystal
positivity. While this gold standard has high specificity,
its feasibility and sensitivity may be inadequate, because
of difficulty with aspiration of joints (particularly small
ones) and/or examination of the sample under polariz-
ing microscopy. Thus, although MSU crystal results are
extremely helpful when positive, they are not a feasible
universal standard, particularly because many potential
study subjects are likely to be recruited from nonrheu-
matology settings. We aimed to develop a new set of cri-
teria that could be flexible enough to enable accurate
classification of gout regardless of MSU status; a
clinical-only version can be considered for use in set-
tings in which synovial fluid or tophus aspiration is not
feasible. Nonetheless, in recognition of its gold standard
status, the expert panel set the presence of MSU crystal
positivity in a symptomatic joint or bursa as sufficient
for classifying an individual as having gout. It should be
recognized that classification criteria are not intended
for use in making a diagnosis in a clinical setting (35).
Thus, in clinical practice, joint or tophus aspiration re-
mains an essential component of establishing a diagno-
sis of gout.
As with most diseases, there is a gradient of prob-
ability of truly having the disease based on signs and
symptoms. The threshold chosen for this classification
criteria set yielded the best combination of sensitivity
and specificity. While for certain purposes a higher sensi-
tivity (lower score) may be preferable (e.g., general pop-
ulation survey to determine the public health burden of
gout for resource planning), a higher specificity (higher
score) may be desirable for others (e.g., genetic associa-
tion studies in which accurate phenotyping is critical).
Furthermore, classification criteria are not intended to
characterize the severity of disease, but only its presence.
Additionally, classification criteria should be applied only
to the intended population—those who meet the entry
criteria. Performance characteristics of any classification
criteria set will necessarily be altered if the criteria are
applied to those other than the intended population.
A limitation of our current effort is that there is
still a relative paucity of data and of clinical experience
to fully test advanced imaging data empirically. As more
studies are published, there may be additional imaging
signs and/or modalities found to have sufficient specific-
ity for gout that could be incorporated into future crite-
ria. We also realized that some investigators may not
have access to imaging and therefore aimed to develop
criteria that would still perform well in the absence of
imaging data. In the discrete-choice experiments, the
lack of imaging data was weighted the same as for stud-
ies performed with negative results, supporting the
validity of using the scoring system in the absence of
imaging data. We did not address asymptomatic hyper-
uricemia, since the purpose of classification criteria is to
identify individuals with a clinical entity for clinical stud-
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ies. There is certainly an interest in studying asymptom-
atic hyperuricemia, but this was beyond the scope of the
current activity; the expert panel agreed that its charge
was to classify individuals with symptomatic disease as
evidence of a clinical condition. The present criteria set
represents an attempt to optimize both sensitivity and
specificity for enrollment into trials and prospective epi-
demiologic studies. Further testing of the criteria in
additional samples, particularly in settings from which
individuals with gout are likely to be recruited (e.g., pri-
mary care), and other study types, is warranted.
This study provides a number of insights relating
to the likelihood of gout. First, the clinical picture of gout
as an episodic disease with stereotypical features and a
predilection for lower-extremity joints, particularly the
first metatarsophalangeal joint, was captured in the
SUGAR study, despite concerns that the study design
might lead to selection bias. Second, there were certain
conditions that strongly reduced the likelihood of gout:
synovial fluid from a symptomatic joint or bursa that was
negative for MSU crystals, and a serum urate level of
,4 mg/dl (0.24 mmoles/liter). While such findings would
not necessarily rule out gout, they were weighted in the
discrete-choice experiments such that they lower the
probability of gout. Third, both the SUGAR subjects and
the paper patient cases were derived from a large interna-
tional pool, supporting generalizability of these criteria.
Finally, advanced imaging modalities have been incorpo-
rated into classification criteria for gout for the first time.
In summary, the 2015 ACR/EULAR classifica-
tion criteria for gout represent an advance over previous
criteria, with improved performance characteristics and
incorporation of newer imaging modalities. These crite-
ria may be considered as inclusion criteria for future
studies of clinical gout.
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